Mr. John Price reports

TELO GENOMICS CORP. ANNOUNCES UPSIZING OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT

Telo Genomics Corp. has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures from up to $1.2-million to up to $1.6-million.

The debentures will bear interest at a rate of 15 per cent per annum, compounded quarterly, and will mature on Dec. 15, 2026. The principal amount of the debentures may, at the holder's election, at any time before the maturity date, be converted into common shares of the company at a conversion price of five cents per share. The company has no right to prepay the debentures prior to the maturity date. For every $100,000 of convertible debentures issued, the company will issue two million detachable warrants. Each warrant will be exercisable to acquire one common share at an exercise price of eight cents per share for a period of 12 months from the closing date.

The company previously closed on an initial tranche of the offering by issuing debentures and 16.8 million warrants for aggregate gross proceeds of $840,000. The company intends to close one or two additional tranches for aggregate gross proceeds of up to $760,000, with the final tranche expected to close on or before March 6, 2026.

The company may pay finders' fees in connection with the upsized offering.

The net proceeds of the upsized offering will be used for working capital and general corporate purposes.

All securities issued pursuant to the upsized offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws.

The upsized offering remains subject to the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining its team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of its proprietary technology have been substantiated in 160-plus peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Its lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.

We seek Safe Harbor.